Cisplatin-Ineligible Urothelial Carcinoma

SAN FRANCISCO — Atezolizumab monotherapy improved OS compared with chemotherapy among patients with PD-L1-high, cisplatin-ineligible metastatic urothelial carcinoma, according to an exploratory analysis of a randomized phase 3 study.

SAN FRANCISCO — Neoadjuvant chemo-immunotherapy led to significant downstaging prior to definitive surgery for patients with muscle-invasive urothelial cancer, according to data presented at ASCO Genitourinary Cancers Symposium.

SAN FRANCISCO — Sacituzumab govitecan induced response among one-third of platinum-ineligible patients with metastatic urothelial carcinoma whose disease progressed after checkpoint inhibitor therapy, according to study results.